Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
30 participants
INTERVENTIONAL
2022-06-14
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental
Fedratinib (Cycle 1: Run-in-Phase with 400 mg QD for 4 weeks, Cycle 2-12: 400 mg QD, Dose modifications will be allowed based on observed toxicity to a 300 mg or a 200 mg daily dose) + Nivolumab (Cycle 2-12: 240 mg, i.v., q2w)
Patients will receive study treatment until loss of response, death or study discontinuation for other reasons.
Fedratinib Oral Capsule [Inrebic]
400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol
Nivolumab
240 mg every 2 weeks i.v. from cycle 2-n
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fedratinib Oral Capsule [Inrebic]
400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol
Nivolumab
240 mg every 2 weeks i.v. from cycle 2-n
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients\* ≥18 years of age
3. diagnosed with myelofibrosis (MF) according to the WHO 2008 or 2016 criteria, including primary (pre-fibrotic or overt) and secondary myelofibrosis.
4. Patients with an indication for therapy (either symptomatic patients with splenomegaly \>11cm diameter and/or symptoms restricting their daily activity or patients with DIPSS int-2, or high risk or MIPSS70 int or high)
5. Patients with no response or suboptimal response to any JAK-inhibitor therapy (regarding persistence of symptoms, splenomegaly, cytopenia or hyperproliferation) defined either by
* Persisting Splenomegaly \>11cm total diameter
* OR Persisting leukoerythroblastosis
* OR Anemia \<6.2 mmol/l (\<10g/dl)
* OR Elevated WBC (\>11 Gpt/l)
* OR Persisting general or constitutional symptoms (persistence is defined as less than 50% reduction to baseline when using the MPN10 TSS Score)
* OR failure \[secondary resistance\] to JAK-inhibitor treatment as defined by IWG-MRT criteria.
6. ECOG performance status \<3 at screening and adequate organ function
7. Reliable contraception should be maintained throughout the study and for 1 month after discontinuation of Fedratinib or 5 months after discontinuation of Nivolumab\*\*
8. Subject must be willing to receive transfusion of blood products
9. Thiamine levels not below lower limit of normal (prior substitution is possible)
10. Normal nutritional status, as judged by the physician
11. Females of childbearing potential (FCBP) must undergo repetitive pregnancy testing (serum or urine) and pregnancy results must be negative.
12. Unless practicing complete abstinence from heterosexual intercourse, sexually active FCBP must agree to use adequate contraceptive methods (i.e. failure rate of \< 1% per year).
13. Males (including those who have had a vasectomy) must use barrier contraception (condoms) when engaging in sexual activity with FCBP. Males must agree not to donate semen or sperm.
Exclusion Criteria
2. \>10% blasts in bone marrow smear (cytology) or \>2x in blood smear within the screening phase or \>20% blasts at any time in bone marrow or peripheral blood smears
3. Creatinine \>2xULN and Creatinine-Clearance \<45ml/min; ALAT, ASAT \& bilirubin \>3xULN (if MF impact on liver \>5xULN)
4. Baseline platelets count below 50 x 10\^9/L and ANC \< 1.0 x 10\^9/L
5. Diagnosis of PV, ET (according to WHO 2016) or positive molecular test for BCR-ABL
6. Patients on ongoing medication for myelofibrosis including systemic corticosteroids (detailed list of permitted medications is provided in paragraph 9.1.10.4 and Appendix V). Use of steroids within 14 days prior to the first dose of study drug and until end of treatment is prohibited by patients.
7. Uncontrolled infection
8. Evidence of acute or chronic infection with hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or tuberculosis
9. Current participation in any other interventional clinical study within 30 days before the first administration of the investigational product or at any time during the study, unless it is an observational (non-interventional) study, or during the follow-up period of an interventional study with last dose of investigational product ≥30 days prior first administration of investigational product within this study.
10. No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician about study participation
11. No consent for biobanking of patient's biological specimens
12. Prior therapy with checkpoint-inhibitors
13. Vaccination within 4 weeks prior to treatment start
14. Hypersensitivity to the IMPs or to any of the excipients
15. History of or uncontrolled autoimmune disease such as autoimmune-hepatitis, -pneumonitis, -thyroiditis, chronic inflammatory bowel disease, multiple sclerosis, or rheumatologic diseases (including but not limited to systemic lupus and vasculitis)
16. History of malignancy except for i) adequately treated local basal cell or squamous cell carcinoma of the skin, ii) asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for ≥ 1 year prior to randomization, or iii) any other cancer that has been in complete remission for ≥ 5 years
17. Secondary malignancy that limits survival to less than 6 months.
18. Drug or alcohol abuse within the last 6 months
19. Patients who cannot adhere to the Pregnancy Prevention Plan
20. Pregnant or breast-feeding females
21. Thiamine levels below normal limit despite supplementation
22. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts \[§ 40 Abs. 1 S. 3 Nr. 3a AMG\]
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prof. F. Heidel, MH Hannover
UNKNOWN
Celgene International II S.á.r.l.
UNKNOWN
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Salah-Eddin Al-Batran, Prof. Dr.
Role: STUDY_DIRECTOR
Institut für Klinische Krebsforschung IKF GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsklinikum Freiburg
Freiburg im Breisgau, , Germany
University Medicine Greifswald
Greifswald, , Germany
Universitätsklinikum Halle (Saale)
Halle, , Germany
Medizinische Hochschule
Hanover, , Germany
Universitätsklinikum Schleswig-Holstein
Lübeck, , Germany
Johannes Wesling Klinikum
Minden, , Germany
Uniklinik Ulm
Ulm, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Isfort S, von Bubnoff N, Al-Ali HK, Becker H, Gotze T, le Coutre P, Griesshammer M, Moskwa C, Wohn L, Riedel J, Palandri F, Manz K, Hochhaus A, Dohner K, Heidel FH. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN). Ann Hematol. 2024 Aug;103(8):2775-2785. doi: 10.1007/s00277-024-05867-w. Epub 2024 Jul 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FRACTION_2021
Identifier Type: -
Identifier Source: org_study_id